Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Puhr

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2017
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen TherapyMartin Puhr, Julia Hoefer, Andrea Eigentler, et al.
Scientific Reports|June 21, 2026
UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancerAnita Csizmarik, Áron Soós, Melinda Váradi, et al.
BJU International|May 27, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancerTibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
Molecular Oncology|June 25, 2020
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastropheStanislav Drápela, Prashant Khirsariya, Wytske M van Weerden, et al.
Molecular Cancer Therapeutics|September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate ModelsFlorian Handle, Martin Puhr, Georg Schaefer, et al.
Endocrine-Related Cancer|March 18, 2010
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivoLei Gu, Paraskevi Vogiatzi, Martin Puhr, et al.
The American Journal of Pathology|August 21, 2024
Inhibition of the Sterol Regulatory Element Binding Protein SREBF-1 Overcomes Docetaxel Resistance in Advanced Prostate CancerMaximilian P Brandt, Olesya Vakhrusheva, Hubert Hackl, et al.
Oncogene|May 15, 2024
Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancerAlicia-Marie K Beier, Celina Ebersbach, Tiziana Siciliano, et al.
International Journal of Cancer|June 11, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancerAnita Csizmarik, Dávid Keresztes, Nikolett Nagy, et al.
Cell Reports. Medicine|January 23, 2024
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancerJing Wang, Jing Wei, Tianjie Pu, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2017
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen TherapyMartin Puhr, Julia Hoefer, Andrea Eigentler, et al.
Scientific Reports|June 21, 2026
UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancerAnita Csizmarik, Áron Soós, Melinda Váradi, et al.
BJU International|May 27, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancerTibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
Molecular Oncology|June 25, 2020
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastropheStanislav Drápela, Prashant Khirsariya, Wytske M van Weerden, et al.
Molecular Cancer Therapeutics|September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate ModelsFlorian Handle, Martin Puhr, Georg Schaefer, et al.
Endocrine-Related Cancer|March 18, 2010
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivoLei Gu, Paraskevi Vogiatzi, Martin Puhr, et al.
The American Journal of Pathology|August 21, 2024
Inhibition of the Sterol Regulatory Element Binding Protein SREBF-1 Overcomes Docetaxel Resistance in Advanced Prostate CancerMaximilian P Brandt, Olesya Vakhrusheva, Hubert Hackl, et al.
Oncogene|May 15, 2024
Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancerAlicia-Marie K Beier, Celina Ebersbach, Tiziana Siciliano, et al.
International Journal of Cancer|June 11, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancerAnita Csizmarik, Dávid Keresztes, Nikolett Nagy, et al.
Cell Reports. Medicine|January 23, 2024
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancerJing Wang, Jing Wei, Tianjie Pu, et al.
Pageof 7